Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Recombinant human hair keratin proteins can effectively stop bleeding.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

KATP channels may help reduce itching in liver disease.

JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Kolaviron and quercetin may help treat prostate issues.

Blocking IL-8 can reduce skin rashes from cancer treatment.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Early immunosuppressive therapy leads to favorable outcomes in Filipino lupus patients with myocarditis.

YWS1903 is safe for pregnant rats at moderate doses but causes fetal issues at high doses.

Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.

Multicomponent crystals in microneedles improve drug delivery for hair loss treatment.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

The compound 4c showed strong potential as an anticancer agent.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Upadacitinib improved multiple immune-related conditions in one patient.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.

Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.